« Return to News | Technology Solutions

IP Shakti launches PipeLinX for open innovation

Wednesday, July 3, 2013 11:30 AM

IP Shakti, an early stage biomedical fund, has launched PipeLinX, a new concept in open innovation solutions. The PipeLinX service sorts through university technology to focus on emerging technologies in the field.

PipeLinX utilizes university technology and intellectual property opportunities. According to the AUTM Licensing Survey (FY2011), universities in the U.S. spent about $61.4 billion on research leading to 21,800 inventions and 19,900 new patent applications. PipeLinX considers the entire U.S. university system, not just the top universities, before narrowing down the number of technologies.

PipeLinX Reports were created to present due diligence information in a format that meets industry standards. Industry scientists, patent attorneys and early stage entrepreneurs provide comprehensive coverage of a technology's strengths and weaknesses. The proprietary scoring system allows for a comparison between technologies and across fields of use. Reports are created that review, compare and rank technologies based on patent, market and technological strengths. Some of the metrics used in the scoring system include the regulatory landscape, attractiveness for licensing and comparable deals.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.